2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Transfusion, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1213 Spectrum landscape of HLH-associated genetic variants in Chinese adolescents and adults: A multi-center cohort analysis

Mengting Yang, Yang Dai, MD2, Yushu Zhong, MD3, Fang Xu4, Jingjing Wen5, Xiaomin Cheng6, Yan Zeng, MD, PhD7, Qiaolin Zhou, MD8, Xu Sun, PhD9, Yushuang Xiao10, Wenyi Liang, MD11, Luocheng Zhang12, Zhuohang Zou13, Bing Xiang14, Yijun Wu, MD15, Ailin Zhao, PhD16, Ting MD, PhD Niu, MD, PhD17
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China
5 Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China
6 Department of Hematology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital, Chengdu, Sichuan, China
7 Department of Hematology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital, Chengdu, Sichuan, China
8 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
10 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
11 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
12 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
13 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, China
14 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
15 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
16 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China
17 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Background: Hemophagocytic lymphohistiocytosis (HLH) is a clinically heterogeneous hyperinflammatory syndrome whose genetic basis may extend beyond the canonical framework of monogenic primary HLH. Here we characterized the spectrum of HLH-related gene variants in Chinese adolescents and adults with HLH and further examined the distribution of variants across different etiologic subgroups.

 Methods: We retrospectively identified patients aged ≥14 years who met the HLH-2004 diagnostic criteria at three centers between August 2018 and February 2026 and had undergone targeted sequencing of HLH-related gene. Sequencing was performed using either a 26-gene panel or an expanded 42-gene panel. Variants classified as pathogenic, likely pathogenic, or variants of uncertain significance according to ACMG criteria were defined as reportable variants and were analyzed at the patient, gene, variant event, and functional pathway levels.

 Results: A total of 272 HLH patients were included and classified according to the underlying etiology into Epstein–Barr virus-associated HLH (EBV-HLH; n = 141, 51.8%), lymphoma-associated HLH (LA-HLH; n = 64, 23.5%), chronic active Epstein–Barr virus disease-associated HLH (CAEBVD-HLH; n = 6, 2.2%), and other HLH (n = 61, 22.4%). Patients ranged in age from 14 to 92 years, with a median age of 38 years at HLH diagnosis. Reportable variants were identified in 160 of 272 patients (58.8%), comprising 243 variant events corresponding to 189 distinct variants across 34 genes. Variants were confined to a single HLH-related gene in 102 patients, whereas 58 harbored variants in multiple genes, most commonly involving UNC13D in combination with PRF1. Most variant events were missense (204, 84.0%) and classified as variants of uncertain significance (VUS; 227, 93.4%). UNC13D was the most frequently affected gene, followed by LYST, DOCK8, RECQL4, and PRF1. UNC13D c.2588G>A (p.Gly863Asp) was the most recurrent variant. Protein-altering variants in UNC13D, RECQL4, LYST, and PRF1 spanned multiple functional domains rather than clustering within a single hotspot. Variants involving cytotoxic granule biogenesis and exocytosis were the most frequently observed pathway across etiologic subgroups, although no significant differences remained after correction for multiple testing.

Conclusions: HLH-related gene variants were common in this large cohort of adolescent and adult patients with HLH and demonstrated broad genetic heterogeneity. The predominance of missense variants and VUS, together with frequent multigene variant patterns, supports a genetic susceptibility model rather than classical monogenic primary HLH. These findings broaden the current understanding of the HLH-related variant spectrum in Chinese patients and may facilitate the interpretation of genetic findings in clinically heterogeneous adolescent and adult HLH.

Mengting Yang: No relevant conflicts of interest to declare.